1 clinical trials for psychiatric or CNS-targeting drugs come with unique challenges. These compounds may affect mood, cognition, or behavior even at sub-therapeutic doses, requiring sensitive and sophisticated safety assessments. Whether developing treatments for depression, schizophrenia, anxiety, or neurodevelopmental disorders, early-phase studies must go beyond traditional PK/PD and incorporate neuropsychiatric monitoring, abuse potential screening, and psychometric tools. This article provides a roadmap for Phase 1 trial design in psychiatric drug development.

Key Objectives of Psychiatric Phase 1 Trials

• Assess CNS safety: Sedation, agitation, dissociation, suicidal ideation
• Characterize PK/PD: Including CNS penetration and target modulation
• Evaluate abuse liability: Particularly for GABAergic, dopaminergic, and NMDA modulators
• Monitor cognition and behavior: Using validated tools and scales

Study Populations

• Healthy volunteers are common unless compound risk is high
• Patients may be used in treatment-resistant or fast-acting antidepressant studies (e.g., ketamine analogs)

Special Design Elements

1. Neuropsychiatric Monitoring

• Structured psychiatric interviews (e.g., MINI, SCID) at screening
• Suicide risk assessment using Columbia-Suicide Severity Rating Scale (C-SSRS)
• Adverse events captured using CNS-specific dictionaries (e.g., MedDRA SOC: psychiatric disorders)

2. CNS Pharmacodynamic Tools

• Pupillometry: Measures autonomic responses and sedation
• Saccadic eye movement: For GABA and NMDA modulators
• EEG or qEEG: For early signal detection
• Functional MRI (optional): Used in exploratory CNS engagement studies

3. Abuse Liability Assessment

• Visual Analog Scales (VAS) for “drug liking” and “euphoria”
• Pupil response, heart rate, and self-reported alertness
• Double-dummy and crossover designs with active comparators like diazepam or amphetamine

PK/PD Considerations

• Include CSF sampling or CNS biomarker analysis if feasible
• Assess central-to-plasma ratios for BBB penetration
• Correlate PD endpoints (e.g., sedation) with C_max and AUC

Ethical Safeguards

• Comprehensive psychiatric screening and exclusion of high-risk volunteers
• On-call psychiatric support during and after dosing
• Daily monitoring for mood changes and suicidal ideation

Regulatory Framework

FDA

• Requires CNS safety data for most psychiatric drugs before Phase 2
• Abuse liability testing required under 21 CFR 314.50
• FDA guidance on CNS active drug development and Schedule V control assessments

EMA

• Emphasizes CNS-specific safety endpoints and neuropsychological testing
• Encourages early PD biomarker integration

CDSCO

• Requires psychiatric screening and consent documentation for CNS-active agents
• Includes additional ethics committee oversight for psychiatric drug trials

Case Example: Novel NMDA Modulator

A biotech company tested a novel antidepressant with NMDA antagonism. Phase 1 included 64 healthy volunteers randomized to receive single and multiple ascending doses. CNS endpoints included:

• EEG and eye movement tracking
• VAS scores for alertness and mood
• Columbia-Suicide Scale assessments

Data revealed dose-dependent CNS effects, with one cohort paused due to dissociative AEs. The trial was adapted to add lower dose tiers and psychiatric support.

Best Practices

• Include psychometricians and neuropsychiatrists on the study team
• Use standardized and validated scales for mood, cognition, and sedation
• Screen out subjects with personal or family history of psychiatric illness unless justified
• Plan for dose modifications, psychiatric adverse events, and protocol amendments